57612-87-0

Basic information

• Product Name: 2-(l,l-dimethylethyl)-6-methoxyphenol
• Synonyms: 2-(l,l-dimethylethyl)-6-methoxyphenol;2-(5-methylisoxazol-3-yl)aceticacid;2-(5-Methyl-1,2-Oxazol-3-Yl)Acetic Acid;EOS-61614
• CAS NO: 57612-87-0
• Molecular Formula: C₆H₇NO₃
• Molecular Weight: 180.24354
• Mol File: 57612-87-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(l,l-dimethylethyl)-6-methoxyphenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(l,l-dimethylethyl)-6-methoxyphenol(57612-87-0)
• EPA Substance Registry System: 2-(l,l-dimethylethyl)-6-methoxyphenol(57612-87-0)

Safety Data

• Hazardous Substances Data: 57612-87-0(Hazardous Substances Data)

Usage

Category

Synthetic antioxidant

Common applications

Food preservation
Personal care products preservation

Derivation

Derived from phenol and isopropyl alcohol

Purpose

Prevents oxidation and spoilage in products like oils, fats, and processed foods

Health concerns

Classified as a possible human carcinogen by the International Agency for Research on Cancer (IARC)
Linked to potential health risks such as skin irritation and hormone disruption

Controversy

Subject to debate due to potential adverse health effects

Regulations

Some countries have imposed restrictions on the use of BHA in food and cosmetics

Upstream product

• 35166-37-1 3-chloromethyl-5-methylisoxazole 
• 35166-41-7 2-(5-methylisoxazol-3-yl)acetonitrile 
• 143-33-9 sodium cyanide 
• 60148-50-7 (5-methyl-isoxazol-3-yl)-acetic acid ethyl ester 

Downstream Products

• 1024012-64-3 C₂₅H₂₆N₆O₂ 
• 130403-07-5 N-(2,6-Dimethyl-phenyl)-2-(5-methyl-isoxazol-3-yl)-acetamide 

Relevant articles and documents

Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Substituted enaminones, their derivatives and uses thereof

The present invention is related substituted enaminones represented by a compound of Formula I that are novel allosteric modulators of α7 nAChRs. The invention also discloses the treatment of disorders that are responsive to enhancement of acetylcholine a